Archean Chemical Industries (ACI) Q3 25/26 earnings summary

Executive summary

• New Managing Director, Rampraveen Swaminathan, appointed, bringing extensive leadership experience in industrials and manufacturing.

• Achieved 10.6% year-over-year revenue growth to Rs. 8,016.7 million for the nine months ended FY26, with exports contributing 79% of total operating revenues.

• Industrial Salt segment revenue rose 29% and volumes increased 39% year-over-year, while Bromine revenues declined 22% and volumes fell 32% due to technical issues.

• Business faced operational challenges in the first half due to erratic monsoons, logistics disruptions, technical plant issues, and a one-time cyclone-related inventory loss, but Q3 showed improved momentum.

• Strategic investments made in semiconductor and energy storage sectors to drive future growth and diversification.

Financial highlights

• Q3 FY26 standalone revenue: INR 2,608.1 million, up 2.4% year-over-year; consolidated revenue: INR 2,615 million.

• Q3 EBITDA: INR 698.6 million (standalone, down 25% YoY), margin at 27%; consolidated EBITDA: INR 613.5 million.

• Q3 net profit: INR 343 million (standalone), INR 240 million (consolidated), impacted by an exceptional cyclone-related loss.

• Nine-month consolidated revenue: INR 8,016.7 million; EBITDA: INR 2,166.5 million; net profit: INR 931.8 million.

• Basic EPS for 9MFY26 was Rs. 7.53, down from Rs. 8.79 in 9MFY25.

Outlook and guidance

• Expectation of stabilization and normalization in the operating environment for the remainder of the year.

• Corrective measures underway to improve Bromine plant efficiencies following production setbacks.

• Bromine production targeted to return to 18,000+ tons in FY27, with a goal to reach 25,000 tons as operational improvements take effect.

• SOP plant-scale trials to commence soon, with meaningful contributions expected in the latter half of FY27.

• Bromine Derivatives utilization targeted to ramp up to 60-70% in FY27 as product portfolio expands.